Claudio Santos

BSc/MSc in Biology (University of Coimbra) and PhD in Microbiology and Genetics (University of Salamanca)
Chief Executive Officer of Gyala Therapeutics and Pulmobiotics (since 2020), where he leads operations, strategy and business development activities and contributes to the scientific development plan of the companies; worked with founders and investor Invivo Capital to set up the companies, raise 3.5m€ in equity and 5.5m€ in non-dilutive funding.
Previously worked as an independent consultant to biotech companies and venture capital funds, as Chief Business Officer at Highlight Therapeutics and Director of Strategic Planning at AdorX Therapeutics (signed strategic partnership with J&J in 2019).
Spent 3 years as an Investment Associate at the CRT Pioneer Fund (managed by Sixth Element Capital, UK) where he led investments in Achilles Therapeutics, Artios Pharma, Neophore Ltd and the “Ras inhibitor program” (partnered with Novartis).
Technology transfer manager at Cancer Research Technology, contributing to technology license agreements with MSD (a deal worth up to $500M) and BioInvent AB
Seven years of experience as a postdoctoral scientist at the London Research Institute, publishing his work in the NEJM, Nature Genetics, Cancer Discovery and Cell Metabolism.